Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Income towards Parent Company (2020 - 2023)

Historic Income towards Parent Company for Terns Pharmaceuticals (TERN) over the last 4 years, with Q4 2023 value amounting to -$21.1 million.

  • Terns Pharmaceuticals' Income towards Parent Company fell 3127.45% to -$21.1 million in Q4 2023 from the same period last year, while for Dec 2023 it was -$90.3 million, marking a year-over-year decrease of 4900.8%. This contributed to the annual value of -$89.6 million for FY2024, which is 78.76% up from last year.
  • According to the latest figures from Q4 2023, Terns Pharmaceuticals' Income towards Parent Company is -$21.1 million, which was down 3127.45% from -$29.8 million recorded in Q3 2023.
  • Terns Pharmaceuticals' 5-year Income towards Parent Company high stood at -$9.2 million for Q1 2020, and its period low was -$29.8 million during Q3 2023.
  • Over the past 4 years, Terns Pharmaceuticals' median Income towards Parent Company value was -$13.9 million (recorded in 2022), while the average stood at -$15.2 million.
  • Its Income towards Parent Company has fluctuated over the past 5 years, first tumbled by 210.51% in 2021, then crashed by 7697.38% in 2023.
  • Over the past 4 years, Terns Pharmaceuticals' Income towards Parent Company (Quarter) stood at -$11.1 million in 2020, then fell by 29.0% to -$14.3 million in 2021, then decreased by 12.07% to -$16.1 million in 2022, then crashed by 31.27% to -$21.1 million in 2023.
  • Its Income towards Parent Company was -$21.1 million in Q4 2023, compared to -$29.8 million in Q3 2023 and -$17.9 million in Q2 2023.